Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies. Academic Article uri icon

Overview

publication date

  • April 1, 2022

Research

keywords

  • Neoplasms
  • Protein Kinase Inhibitors

Identity

PubMed Central ID

  • PMC8968902

Scopus Document Identifier

  • 85127883243

Digital Object Identifier (DOI)

  • 10.3324/haematol.2021.280061

PubMed ID

  • 34937320

Additional Document Info

volume

  • 107

issue

  • 4